Home > BBI Solutions Licenses 3DNA® Signal Amplification Technology from Genisphere for Lateral Flow Rapid Test Applications
News & Events

BBI Solutions Licenses 3DNA® Signal Amplification Technology from Genisphere for Lateral Flow Rapid Test Applications

HATFIELD, Pa -
November 10, 2014 -

CARDIFF, U.K. – BBI Solutions (BBI), part of the BBI Group, a trusted partner to some of the world’s leading diagnostic and healthcare organisations for over 25 years, today announced it has signed an agreement to license 3DNA® Signal Amplification technology from Genisphere, LLC for development of lateral flow rapid test applications. BBI will utilise the technology to develop lateral flow assays with enhanced performance and sensitivity, particularly for assay development and manufacturing services for the point-of-care diagnostic market. The parties also agreed to negotiate further licenses to permit BBI to commercialize such products. The financial terms of the partnership were not disclosed.

“A key goal for rapid test manufacturers is to push the level of detection to the absolute maximum”, said Leigh Thomas, Chief Commercial Officer at BBI Solutions. “We believe that Genisphere’s 3DNA Signal Amplification technology will provide BBI with an additional valuable tool to drive assay performance, expand the life cycle of lateral flow assays, and offer lateral flow solutions to enable the level of handheld POC analysis that may not have been previously possible.” Genisphere’s 3DNA technology has been used to improve the limit of detection in a variety of assay platforms, including microarray, ELISA, bead-based flow cytometry and lateral flow. The technology can provide a significant improvement in sensitivity where conventional optimisation methods have not delivered the required performance.

The formal partnership between the companies has resulted from a three-year R&D collaboration focused on customising the 3DNA technology to BBI’s rapid test platforms and those of its customers. “Genisphere is delighted to have this relationship with BBI, a market leader in lateral flow rapid test development and manufacturing,” said Jim Kadushin, Genisphere's chief operations officer. “Our combined efforts will result in BBI providing its partners with an edge in this competitive landscape, and the true winner will be the patient.”

BBI will be showcasing the benefits of the 3DNA Signal Amplification technology in lateral flow applications at the Medica exhibition in Dusseldorf from 12th to 15th November 2014.

About BBI

BBI Solutions is a leading manufacturer of raw materials and finished test platforms for the in-vitro diagnostics market. With over 50 years’ experience, BBI has grown from a small specialist company to a global business with manufacturing sites spanning three countries.

Our range of raw materials includes human antigens, antibodies, serum and plasma products and clinical chemistry enzymes. We manufacture world renowned labels for lateral flow, ELISA assay and biosensors, including our gold nanoparticles and glucose oxidase.

BBI Solutions also offer leading edge development and manufacturing services across a number of lateral flow and related platforms. BBI Solutions is part of the BBI Group.

For more information visit: www.bbisolutions.com

Contact:
Carly Unsworth
Senior Marketing Manager T: +44 (0) 2920 747 232
E: CarlyUnsworth@bbisolutions.com

About Genisphere

Genisphere LLC is the provider of the 3DNA® platform for targeted drug delivery. 3DNA® is a nanoscale, multivalent scaffold made from proprietary, synthetic DNA formed in a flexible, branched structure. 3DNA® nanocarriers are engineered and cross-linked to form a stable architecture while maintaining the biocompatibility of the nucleic-acid building blocks, and demonstrate efficacy and safety with a variety of drug cargos across multiple indications. Genisphere's technology is IP-protected and fully customizable to deliver small molecules, biologics, and nucleic acids with precise specificity enabled by multivalent targeting via antibodies, peptides and other molecular entities. Genisphere leverages a collaborative model to advance its 3DNA® drug delivery platform, and seeks additional partnerships with biotechnology and pharmaceutical companies to improve efficacy and reduce toxicity. Genisphere is also advancing its own lead compounds based on 3DNA® nanotechnology. For more information, please visit http://genisphere.com.

For more information contact:

Tom Bliss
CEO, Genisphere